A Prospective, Single Arm, Open-Label Phase 2 Study to Characterize the Safety and Hemostatic Actifity of Topical Firocaps in Surgical Hemostasis

StatusFinished
Effective start/end date6/07/1031/08/13

Funding

  • ProFibrix: $85,306.25

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research